Influence of applied tension and nitric oxide on responses to endothelins in rat pulmonary resistance arteries: effect of chronic hypoxia

British Journal of Pharmacology
M R MacLean, K M McCulloch

Abstract

1. The effect of basal tension (transmural tensions 235 +/- 29 mg wt (low tension: equivalent to approximately 16 mmHg) and 305 +/- 34 mg wt (high tension: equivalent to 35 mmHg)) on rat pulmonary resistance artery responses to endothelin-1 (ET-1) and the selective ET(B)-receptor agonist sarafotoxin S6c (S6c) were studied. The effects of nitric oxide synthase inhibition with N(omega)-nitro-L-arginine methylester (L-NAME, 100 microM) on ET receptor-induced responses, as well as vasodilator responses to acetylcholine (ACh) and S6c, were also investigated. Changes with development of pulmonary hypertension, induced by two weeks of chronic hypoxia, were determined. 2. Control rat preparations showed greatest sensitivity for ET-1 when put under low tension (pEC50: 8.1 +/- 0.1) compared with at the higher tension (pEC50: 7.7 +/- 0.1) and there were significant increases in maximum contractile responses to S6c (approximately 80%) and noradrenaline (approximately 60%) when put under high tension. 3. In control pulmonary resistance arteries, both ET-1 and S6c produced potent vasoconstrictor responses. S6c was 12 fold more potent than ET-1 in vessels set at low tension (S6c pEC50: 9.2 +/- 0.1) and 200 fold more potent than ET-1 when the ...Continue Reading

References

Mar 25, 1991·Biochemical and Biophysical Research Communications·D L WilliamsB V Clineschmidt
Mar 15, 1991·Annals of Internal Medicine·D J StewartD Langleben
Oct 1, 1988·Circulation Research·B Tesfamariam, R A Cohen
Apr 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·A InoueT Masaki
Mar 1, 1974·Clinical Science and Molecular Medicine·C HunterE J Clegg
May 1, 1994·Journal of Cardiovascular Pharmacology·M R MacLeanM Baird
Jan 1, 1995·Trends in Pharmacological Sciences·C J GarlandT M Cocks
May 1, 1994·Journal of Applied Physiology·T FukurodaM Nishikibe
Mar 1, 1996·The American Journal of Physiology·T C Resta, B R Walker
Jul 1, 1996·British Journal of Pharmacology·D W HayE H Ohlstein
Sep 1, 1996·British Journal of Pharmacology·X NorelC Brink
Nov 1, 1996·British Journal of Pharmacology·K M McCullochM R MacLean
Feb 1, 1997·The American Journal of Physiology·T C RestaB R Walker

❮ Previous
Next ❯

Citations

Jul 28, 1999·European Journal of Pharmacology·R D JonesA H Morice
Jul 20, 2002·Respiratory Physiology & Neurobiology·Philip I AaronsonJeremy P T Ward
Aug 28, 1998·British Journal of Pharmacology·C Docherty, M R MacLean
Mar 23, 2011·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Dongmin ShaoStephen J Wort
Nov 26, 2005·European Journal of Pharmacology·Lucie GoretPhilippe Obert
Apr 5, 2008·Journal of Applied Physiology·Qin XueLubo Zhang
Sep 19, 2012·Journal of Cardiovascular Pharmacology·Robert M Rapoport, Mario Zuccarello
Jun 19, 2001·American Journal of Physiology. Lung Cellular and Molecular Physiology·S BonnetJ P Savineau
Oct 4, 2000·Physiological Reviews·V Hampl, J Herget

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.